Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers

European Journal of Cancer

Volumn 45, Issue 13, 2009, Pages 2333-2341

  Soria, J C ^a   Massard, C ^a   Magne N ^a   Bader, Th ^b   Mansfield, C D ^b   Blay, J Y ^c   Bui, B N ^d   Moussy, A ^b   Hermine, O ^e   Armand, J P ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b AB Science   (France)

^c CENTRE LÉON BÉRARD   (France)

^d INSTITUT BERGONIÉ   (France)

^e CNRS   (France)

Author keywords

c Kit; GIST; Imatinib; Masitinib; Phase 1 study; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB; MASITINIB; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LYMPHATIC SYSTEM DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; METASTASIS; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES; THIAZOLES; TREATMENT OUTCOME;

EID: 68949166379     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.010     Document Type: Article

References (19)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
2. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., and Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 3 (2000) 925-932
3. Heinrich M.C., Blanke C.D., Druker B.J., and Corless C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20 6 (2002) 1692-1703
4. Lennartsson J., Jelacic T., Linnekin D., and Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 23 1 (2005) 16-43
5. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 5350 (1998) 577-580
6. Miettinen M., and Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 54 1 (2003) 3-24
7. Miettinen M., and Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130 10 (2006) 1466-1478
8. Sleijfer S., Wiemer E., and Verweij J. Drug Insight: gastrointestinal stromal tumors (GIST) - the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol 5 2 (2008) 102-111
9. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
10. Deininger M., Buchdunger E., and Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 7 (2005) 2640-2653
11. Provenzano P.P., Inman D.R., Eliceiri K.W., Beggs H.E., and Keely P.J. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol 173 5 (2008) 1551-1565
12. Hernandez-Hansen V., Mackay G.A., Lowell C.A., Wilson B.S., and Oliver J.M. The Src kinase Lyn is a negative regulator of mast cell proliferation. J Leukoc Biol 75 1 (2004) 143-151
13. Linnekin D., DeBerry C.S., and Mou S. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J Biol Chem 272 43 (1997) 27450-27455
14. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12 8 (2006) 908-916
15. Judson I., and Demetri G. Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol 18 Suppl. 10 (2007) 20-24
16. Goodman V.L., Rock E.P., Dagher R., Ramchandani R.P., Abraham S., Gobburu J.V., et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13 5 (2007) 1367-1373
17. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 9604 (2007) 2011-2019
18. Deininger M.W. Nilotinib. Clin Cancer Res 14 13 (2008) 4027-4031
19. Weisberg E., Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Ray A., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 2 (2005) 129-141